はじめての方へショーケース価格
  1. 米国企業
  2. Vir Biotechnology, Inc.

Vir Biotechnology, Inc.VIR

時価総額
$13.1億
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日		2023年
12月31日
Net (loss) income-175-299---615
Changes in estimated constraint on profit-sharing amount-----28
Depreciation and amortization34--19
Amortization of intangible assets11111
Accretion of discounts on investments, net0-2--9
Noncash lease expense-3--8
Assets, Fair Value Adjustment----22
Change in estimated fair value of contingent consideration----1
Stock-based compensation928--111
Change in deferred income taxes-0--1
Impairment of Intangible Assets, Finite-Lived-1--10
Impairment, Long-Lived Asset, Held-for-Use----8
Payment of contingent consideration in excess of acquisition date fair value--16---
Other-0--0
Receivable from collaboration----1
Prepaid expenses and other current assets54439-65
Other assets21112-2
Accounts payable1-1--1
Accrued liabilities and other long-term liabilities104758-16-356
Operating lease liabilities-----13
Deferred revenue4-7---2
Net cash (used in) provided by operating activities-130-191---779
Purchases of property and equipment97--22
Purchases of investments644404--2,016
Maturities and sales of investments397400--2,202
Net cash provided by (used in) investing activities-256-10--165
Proceeds from Stock Plans----4
Proceeds from Stock Options Exercised14--3
Payment of principal on financing lease obligations00--0
Proceeds from Noncontrolling Interests----0
Increase in ownership interest in a subsidiary----0
Payment of contingent consideration-4---
Net cash provided by financing activities449529--7
Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents63329---607
Income Taxes Paid, Net----3